Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04193306
Other study ID # ACAV2018
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date November 18, 2019
Est. completion date July 2025

Study information

Verified date September 2023
Source Institute for Clinical and Experimental Medicine
Contact Vojtech Melenovsky, MD, PhD
Phone 420 739 528 029
Email vojtech.melenovsky@ikem.cz
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cardiac allograft vasculopathy (CAV) represents the leading cause of late morbidity and mortality in heart transplant recipients as the second most frequent cause of all deaths at 3 years. In distinction from general coronary atherosclerosis, CAV affects diffusely the entire coronary vasculature with marked intimal proliferation and concentric vascular thickening and fibrosis. It was demonstrated that most of the intimal thickening due to CAV occurs during the first year after transplantation. Furthermore, the severity of the CAV appears to correlate with lipid abnormalities and elevated low-density lipoprotein cholesterol (LDL-C) is very common after transplantation with nadir of LDL levels occurring at 6 months. Because of drug-drug interactions, heart transplant recipients cannot be treated with adequate doses of statins to achieve desirable reduction of LDL-C levels (reduction ˂ 60% of LDL-C). The use of alternative lipid-lowering drugs including bile acid sequestrates, fibrates, nicotinic acid or ezetimibe is not recommended in post-transplant scenario. Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) increase availability has emerged as a novel drug tool for LDL-C lowering, capable to lower LDL-C by more than 60% even in statin-treated patients with very good safety profile. Although heart transplant recipients fulfill approved indication and standard clinical guidelines of a PCSK9 inhibitor, alirocumab, there are no available data on use of PCSK9 inhibitor in post-transplant situation. The purpose of the ACAV study is to clarify efficacy and safety of alirocumab compared to placebo administered during the first year after transplantation in heart transplant recipients in addition to background atorvastatin therapy. Except lipid profile, optical coherence tomography (OCT) will be performed as the objective efficacy endpoint to examine thickness and lumen of coronary vessels. It is expected that inhibition of PCSK9 in heart transplant recipient will dramatically improve post-transplant lipoprotein levels and perhaps slow down development of CAV in the most critical period of the first year after transplantation.


Description:

This is a double-blind, placebo-controlled, randomized, prospective, phase IV trial with parallel design. 126 of new cardiac transplant recipients are planned to be enrolled in two sites: 1) Transplant Centre at Institute for Clinical and Experimental Medicine, Prague, Czech Republic, and 2) St Anne's University Hospital (FNUSA) - Centre of Cardiovascular and Transplant Surgery (CKTCH) in Brno, Czech Republic. Screening data will be reviewed to determine subject eligibility. Subjects who meet all inclusion criteria and none of the exclusion criteria will be entered into the study. Screening period could last up to four weeks. Subjects will be randomized 1:1 to receive either alirocumab 150 mg every 2 weeks or placebo between month 1 and month 12 after transplantation (study treatment will start after the first surveillance cardiac catheterization approximately one month after heart transplantation and it will be completed after the second surveillance cardiac catheterization approximately 12 months after heart transplantation). Furthermore, all subjects will be on a background statin treatment with atorvastatin 10 mg daily. After Screening and Baseline visit, 5 visits are planned during the treatment period (4, 8, 20, 34 and 48 weeks after baseline) and follow-up visit is planned 60 weeks after baseline. Maximal expected duration of subject participation will be 15 months.


Recruitment information / eligibility

Status Recruiting
Enrollment 126
Est. completion date July 2025
Est. primary completion date May 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. New cardiac transplant recipient = 18 years of age willing to participate in the study. 2. Ability to understand study procedures and to comply with them for the entire length of the study. 3. Written informed consent obtained from subject or subject's legal representative. 4. Heart transplantation surgery performed 3 - 8 weeks before the baseline visit. Exclusion Criteria: 1. Known hypersensitivity/allergy reaction to study medication. 2. Complicated post-transplant outcome with poor neurological status, multiorgan failure or graft dysfunction. 3. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data. 4. Lipoprotein apheresis is planned of performed. 5. Level of LDL-C = 8 mmol/L at screening. 6. Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study. 7. Participation in any other interventional study. Known hypersensitivity/allergy to contrast agent or severe renal insufficiency (eGFR ? 30 mL/min/1.75 m2) exclude patient from OCT imaging only, not from the whole study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Alirocumab
Alirocumab 150 mg s.c. every 2 weeks
Other:
Placebo
Placebo s.c. every 2 weeks

Locations

Country Name City State
Czechia Institute for Clinical and Experimental Medicine Prague

Sponsors (1)

Lead Sponsor Collaborator
Institute for Clinical and Experimental Medicine

Country where clinical trial is conducted

Czechia, 

References & Publications (2)

Chen Z, Pazdernik M, Zhang H, Wahle A, Guo Z, Bedanova H, Kautzner J, Melenovsky V, Kovarnik T, Sonka M. Quantitative 3D Analysis of Coronary Wall Morphology in Heart Transplant Patients: OCT-Assessed Cardiac Allograft Vasculopathy Progression. Med Image Anal. 2018 Dec;50:95-105. doi: 10.1016/j.media.2018.09.003. Epub 2018 Sep 14. — View Citation

Pazdernik M, Chen Z, Bedanova H, Kautzner J, Melenovsky V, Karmazin V, Malek I, Tomasek A, Ozabalova E, Krejci J, Franekova J, Wahle A, Zhang H, Kovarnik T, Sonka M. Early detection of cardiac allograft vasculopathy using highly automated 3-dimensional optical coherence tomography analysis. J Heart Lung Transplant. 2018 Aug;37(8):992-1000. doi: 10.1016/j.healun.2018.04.002. Epub 2018 Apr 6. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary calculated LDL cholesterol concentration the difference in mean of values from visits 2,3,4,5 and 6 between alirocumab/placebo arms the time period between 2 and 12 months after heart transplantation
Primary HDL cholesterol concentration the difference in mean of values from visits 2,3,4,5 and 6 between alirocumab/placebo arms the time period between 2 and 12 months after heart transplantation
Primary total cholesterol the difference in mean of values from visits 2,3,4,5 and 6 between alirocumab/placebo arms the time period between 2 and 12 months after heart transplantation
Primary triglycerides the difference in mean of values from visits 2,3,4,5 and 6 between alirocumab/placebo arms the time period between 2 and 12 months after heart transplantation
Primary ApoB the difference in mean of values from visits 2,3,4,5 and 6 between alirocumab/placebo arms the time period between 2 and 12 months after heart transplantation
Primary Lp (a) the difference in mean of values from visits 2,3,4,5 and 6 between alirocumab/placebo arms the time period between 2 and 12 months after heart transplantation
Primary Apo A1 the difference in mean of values from visits 2, 3, 4 ,5 and 6 between alirocumab/placebo arms the time period between 2 and 12 months after heart transplantation
Secondary calculated LDL cholesterol concentration Percent change from baseline (visit 1) to visit 6 between alirocumab/placebo arms between 1 and 12 months after heart transplantation
Secondary calculated LDL cholesterol concentration Difference in values at every study visit between alirocumab/placebo arms between 1 and 12 months after heart transplantation
Secondary lipid parameters values Difference in values at every study visit between alirocumab/placebo arms between 1 and 12 months after heart transplantation
Secondary calculated LDL cholesterol concentration Difference in values at visit 6 compared to visit 7 between alirocumab/placebo arms between 12 and 15 months after heart transplantation
Secondary lipid parameters values Difference in values at visit 6 compared to visit 7 between alirocumab/placebo arms between 12 and 15 months after heart transplantation
Secondary mean intimal thickness assessed by OCT Percent change from baseline (visit 1) to visit 6 between alirocumab/placebo arms 1 and 12 months after heart transplantation
Secondary mean lumen volume assessed by OCT Percent change from baseline (visit 1) to visit 6 between alirocumab/placebo arms 1 and 12 months after heart transplantation
Secondary incidence of adverse events Assessment of safety of alirocumab in comparison to placebo 1 and 15 months after heart transplantation
See also
  Status Clinical Trial Phase
Completed NCT02880137 - Real Time Myocardial Perfusion Echocardiography for Coronary Allograft Vasculopathy Phase 4
Terminated NCT01848301 - Endothelial Injury and Development of Coronary Intimal Thickening After Heart Transplantation Phase 1
Terminated NCT01278745 - Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation Phase 2
Withdrawn NCT01812434 - Phosphodiesterase-5 (PDE-5) Inhibition in Heart Transplant Recipients N/A
Withdrawn NCT01305382 - Noninvasive Evaluation of Cardiac Allograft Vasculopathy N/A
Recruiting NCT05826444 - Microvascular Cardiac Allograft Vasculopathy Trial
Suspended NCT05756088 - Determining the Association of Microvascular Disease as Assessed by PET and Graft Injury by Donor Derived Cell Free DNA
Completed NCT02013037 - The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation Phase 3
Withdrawn NCT01305395 - Strategies To Prevent Cardiac Allograft Vasculopathy Related Events in Heart Transplant Recipients N/A
Withdrawn NCT01157949 - A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV) Phase 3
Enrolling by invitation NCT06147271 - Impact of SGLT2 Inhibitors in Heart Transplant Recipients Phase 2
Recruiting NCT02798731 - Physiologic Assessment of Microvascular Function in Heart Transplant Patients
Withdrawn NCT02777255 - Severe CAV MRI in Heart Transplant Recipient N/A
Completed NCT05373108 - Endothelin-1 and Cardiac Allograft Vasculopathy (CAV) Phase 4
Withdrawn NCT01424917 - Noninvasive Predictors of Transplant Vasculopathy N/A
Recruiting NCT04770012 - AERIAL Trial: Antiplatelet Therapy in Heart Transplantation Phase 3
Active, not recruiting NCT01078363 - Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy N/A
Completed NCT03734211 - Cholesterol Lowering With EVOLocumab to Prevent Cardiac Allograft Vasculopathy in De-novo Heart Transplant Recipients Phase 3
Recruiting NCT06089486 - MARINER Trial: Multiparametric Cardiac PET for CAV Surveillance After Heart Transplantation N/A
Active, not recruiting NCT03386539 - Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score Phase 3